Meridian Health Plan of Illinois Launches Telehealth for YouthCare Members via Blueberry Pediatrics
Meridian Health Plan of Illinois, a provider of managed care services for children, families, and individuals with complex medical needs, has expanded its telehealth program with Blueberry Pediatrics. Initially launched as a pilot in March 2024, the program will now…
Elation Health Survey: 66% of Primary Care Docs Say AI Reduces Administrative Burden
Elation Health, a clinical-first technology company driving innovation in primary care, today shared the results of its latest survey of 100 primary care physicians (PCPs). The survey provides valuable insights into the adoption and impact of artificial intelligence (AI) in…
Bristol Myers Squibb Gets CHMP Nod for Opdivo + Yervoy in MSI-High Colorectal Cancer
Bristol Myers Squibb (NYSE: BMY) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending the approval of Opdivo® (nivolumab) in combination with Yervoy® (ipilimumab) for the first-line…
HCA Healthcare Named Best Employer for Veterans by Military Times for Fifth Year
HCA Healthcare, one of the nation’s leading healthcare providers, has been named a Best for Vets Employer by Military Times for the fifth consecutive year, in recognition of its ongoing efforts to recruit, mentor, and retain U.S. service members. Since…
Vektor Medical’s AI-Powered vMap Achieves 91% Accuracy in Distinguishing Ventricular Tachycardia Types
Vektor Medical, a leader in non-invasive arrhythmia analysis and localization, today announced new data demonstrating the enhanced capabilities of its AI-powered solution, vMap, for improving cardiac arrhythmia treatment. The data, to be presented at the American Heart Association (AHA) Scientific…
Cofactor Genomics Expands OncoPrism Use After National Validation for Lung Cancer Immunotherapy
Cofactor Genomics, Inc., a clinical-stage company focused on bridging the precision medicine gap through RNA decoding, today announced the validation and launch of OncoPrism®-NSCLC, an RNA-based diagnostic test designed to predict response to immune checkpoint inhibitors (ICI) in patients with…
Synthekine to Present Preclinical Data for CD19 CAR-T (SYNCAR-001) with STK-009 at ACR Convergence 2024
Synthekine Inc., a company specializing in engineered cytokine therapeutics, today announced that promising preclinical results from its murine STK-009 + SYNCAR-001 program will be presented at the American College of Rheumatology (ACR) Convergence 2024 in Washington, D.C. The data highlights…
Exact Sciences Presents Promising Multi-Cancer Detection Data at AACR Liquid Biopsy Conference
Exact Sciences Corp. (NASDAQ: EXAS), a leader in cancer screening and diagnostic tests, will present three key abstracts at the American Association for Cancer Research (AACR) Special Conference on Liquid Biopsy, taking place November 13-16, 2024, in San Diego, CA.…
Bumrungrad Hospital Enhances Patient Experience with Certinal eSign Solution
Certinal eSign, a leader in Digital Transaction Management, has strengthened its strategic partnership with Bumrungrad International Hospital, a globally recognized healthcare provider, to revolutionize patient registration and data management. This expanded collaboration will drive greater efficiencies, improve security, and transform…
DiaMedica Doses First Patient in Phase 2 Preeclampsia Trial of DM199
DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing innovative treatments for severe ischemic diseases, today announced that the first patient has been dosed in its investigator-sponsored Phase 2 trial of DM199 for preeclampsia (PE). The company…
Quince Therapeutics Presents Phase 3 ATTeST Trial Safety Data at CNS Annual Meeting
Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company focused on using patients’ own biology to treat rare diseases, presented safety data from its Phase 3 ATTeST (Ataxia-Telangiectasia Trial with the EryDex SysTem) clinical trial at the 53rd Child Neurology…
Geron Corporation Appoints Joseph Eid, M.D. as EVP of R&D
Geron Corporation (Nasdaq: GERN), a biopharmaceutical leader focused on transforming the treatment of blood cancers, announced today the appointment of Joseph Eid, M.D., as Executive Vice President of Research and Development (R&D), effective November 11, 2024. In his new role,…